FDA Drug Label
SAXENDA (liraglutide) injection — Prescribing Information
Novo, 2014
GLP-1 & MetabolicFDA ApprovedS
Liraglutide
Victoza / Saxenda
Liraglutide (Victoza for T2D, Saxenda for obesity) is Novo Nordisk's FDA-approved once-daily injectable GLP-1 receptor agonist. SCALE obesity trial demonstrated 5–8% body weight reduction and significant HbA1c reduction. While largely superseded by once-weekly semaglutide and tirzepatide for weight loss, Liraglutide remains a cornerstone type 2 diabetes treatment and has a robust cardiovascular outcomes trial (LEADER) demonstrating cardiovascular risk reduction.
Observational report only — live community data. Not medical advice. Does not recommend doses, protocols, or treatments.
- Studies cited
- 8
- Research grade
- S
- Experience
- 100
- Activity
- 92
Overall check-ins
Trackers & reports
Overview
About Liraglutide
Liraglutide (Victoza for T2D, Saxenda for obesity) is Novo Nordisk's FDA-approved once-daily injectable GLP-1 receptor agonist. SCALE obesity trial demonstrated 5–8% body weight reduction and significant HbA1c reduction. While largely superseded by once-weekly semaglutide and tirzepatide for weight loss, Liraglutide remains a cornerstone type 2 diabetes treatment and has a robust cardiovascular outcomes trial (LEADER) demonstrating cardiovascular risk reduction.
- Category
- GLP-1 & Metabolic
- Regulatory status
- FDA Approved
- Also known as
- Victoza / Saxenda
- Self-reports
- 6
Community
What 6 users report
6 community reports
Overall experience
From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Favorable 100% · Mixed 0% · Unfavorable overall 0%
Most reported benefits
Benefits users selected when logging a favorable or mixed check-in.
Appetite
6
Self-reported dose per injection
Median bucket: 2+ mg · Most common: 2+ mg
Reports span 1 to ≥ 2 mg (open-ended top bucket)
1–2 mg
2
2+ mg
4
Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.
Commonly stacked with
Research
Cited research (6)
Source
FDA Drug Label
VICTOZA (liraglutide) injection — Prescribing Information
Novo, 2010
PubMed
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes (LEADER trial)
Marso et al., 2016
PubMed
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management (SCALE)
Pi-Sunyer et al., 2015
PubMed
Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial
Rubino et al., 2022
PubMed
Efficacy and Safety of Liraglutide 3.0 mg in Individuals With Overweight or Obesity and Type 2 Diabetes Treated With Basal Insulin: The SCALE Insulin Randomized Controlled Trial
Garvey et al., 2020
Tools
Explore more
Explore
More ways to learn about Liraglutide from observational PeptIQ data.
Compare with
Related peptides
Help
Frequently asked
What do PeptIQ users report about Liraglutide?
This page summarizes 6 anonymized self-reports from PeptIQ users who track Liraglutide, including commonly reported effects and co-tracked peptides. These are observational patterns, not clinical outcomes.
How do side effects relate to overall experience for Liraglutide?
PeptIQ separates overall check-in ratings (favorable, mixed, or unfavorable) from logged side effects like nausea or fatigue. Users often report benefits and side effects in the same check-in — a high experience score does not mean zero side effects were noted.
What research is cited for Liraglutide?
6 sources are linked on this page, including PubMed articles, clinical trial registries, and FDA labels where applicable. Citations describe published research — not recommendations.
Is Liraglutide safe to use?
This wiki does not assess safety or recommend use. Liraglutide is listed as FDA Approved. Consult a licensed clinician for personal medical decisions.
What are the purported benefits and uses of Liraglutide?
Research, primarily in animal models, suggests Liraglutide may have a wide range of therapeutic potentials due to its ability to promote angiogenesis (formation of new blood vessels), stimulate collagen synthesis, and modulate inflammatory responses.
SourceWhat is the legal status of Liraglutide?
Liraglutide is not approved by the FDA for any human use. There is no legal basis for selling it as a drug, food, or dietary supplement in the United States. The FDA has classified Liraglutide as a Category 2 bulk drug substance, which explicitly prohibits licensed compounding pharmacies from using it in compounded medications.
SourceWhat are the known or theoretical side effects and risks of Liraglutide?
The safety and effectiveness of Liraglutide have not been thoroughly evaluated in humans through rigorous clinical trials. This lack of human data means that safe dosages, short-term side effects, and long-term health consequences are largely unknown.
SourceWhat is the current state of research on Liraglutide?
While there are over 200 published studies on Liraglutide, the vast majority are animal or in vitro (cell) studies. These preclinical studies consistently show positive results across various tissue types. However, there is a significant lack of comprehensive human clinical trial data.
Source